In 2018, developments in Parkinson disease (PD) research yielded improved diagnostic criteria and provided evidence for the effects of some treatments, both old and new. These developments enrich the treatment options available for PD and are likely to change important guideline recommendations.
The new diagnostic criteria for Parkinson disease (PD) yield high diagnostic specificity, but modest sensitivity2.
Although many drugs have failed to protect against disease progression in trials, exenatide is a promising new candidate5.
Subcutaneous infusion of apomorphine, a dopamine agonist, shortens the off-time of patients with advanced PD according to a confirmatory double-blind study6.
A secondary analysis of a trial testing deep brain stimulation of the subthalamic nucleus against the best available medical treatment has shown that it improves impulse control disorders8.
Pulsed focused ultrasound lesioning, an invasive procedure without incision, was successfully used in the subthalamic nucleus as a treatment of PD with motor response fluctuations10.
Your institute does not have access to this article
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Berg, D. et al. Movement disorder society criteria for clinically established early Parkinson’s disease. Mov. Disord. 33, 1643–1646 (2018).
Postuma, R. B. et al. Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 33, 1601–1608 (2018).
Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664–1675 (2017).
Athauda, D. et al. What effects might exenatide have on non-motor symptoms in Parkinson’s disease: a post hoc analysis. J. Parkinsons Dis. 8, 247–258 (2018).
Athauda, D. et al. Post hoc analysis of the exenatide-PD trial-factors that predict response. Eur. J. Neurosci. https://doi.org/10.1111/ejn.14096 (2018).
Katzenschlager, R. et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 17, 749–759 (2018).
Corvol, J. C. et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91, e189–e201 (2018).
Lhommee, E. et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 17, 223–231 (2018).
Elias, W. J. A trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 375, 2202–2203 (2016).
Martinez-Fernandez, R. et al. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson’s disease: a pilot study. Lancet Neurol. 17, 54–63 (2018).
G.D. has received lecture fees from Boston Scientific and has been serving as a consultant for Boston Scientific. He received royalties from Thieme publishers. He is a government employee and receives through his institution funding for his research from the German Research Council, the German Ministry of Education and Research and Medtronic. R.M.A.de B. reports grants from ZonMw, Parkinson Vereniging (Netherlands patient organization), Stichting ParkinsonFonds (charitable foundation) and Stichting Parkinson Nederland (charitable foundation), and unrestricted research grants from GE Health and from Medtronic.
About this article
Cite this article
Deuschl, G., de Bie, R.M.A. New therapeutic developments for Parkinson disease. Nat Rev Neurol 15, 68–69 (2019). https://doi.org/10.1038/s41582-019-0133-0